Tests a radioactive drug, 225Ac-ETN029, in adults with advanced DLL3-positive cancers
Tests a radiation-carrying drug in adults with advanced DLL3-positive neuroendocrine cancers.
Plain-language title generated from the registry record
Registry title: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Key facts
- Where
- Barcelona and Madrid, SpainSee the 2 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or spread DLL3-positive cancers, such as small cell lung cancer or neuroendocrine carcinomas, whose disease got worse after earlier treatment.
- Age
- 18 Years to 100 Years
- Sex
- All sexes can join.
- Disease stage
- Locally advanced, unresectable or metastatic cancer. Types include small cell lung cancer, large cell neuroendocrine carcinoma of the lung, neuroendocrine prostate cancer, other neuroendocrine carcinomas, Merkel cell carcinoma and medullary thyroid cancer (dose escalation only). Some groups need a measurable lesion that shows 111In-ETN029 uptake on SPECT/CT.
- Earlier treatment
- Disease got worse after, or the person could not tolerate, at least 1 line of systemic therapy, including platinum-containing chemotherapy for most types. Small cell lung cancer in the expansion part: no more than 2 prior lines. Any prior radioligand therapy (RLT) is not allowed, except for neuroendocrine prostate cancer in the expansion part. Any prior DLL3-targeted therapy is not allowed, except for small cell lung cancer.
- Biomarker or test result
- The cancer must express DLL3. Neuroendocrine prostate cancer must have marker expression (e.g., chromogranin, synaptophysin) confirmed by local IHC in the expansion part.
Main reasons for not taking part
- Low blood counts: ANC < 1.0 x 10^9/L, hemoglobin < 9 g/dL or platelets < 75 x 10^9/L
- QTcF ≥ 470 msec
- eGFR < 60 mL/min/1.73m2
- Unmanageable urinary tract obstruction or urinary incontinence
- Leptomeningeal disease, symptomatic CNS metastases, or CNS metastases needing local CNS-directed therapy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07006727, who can take part
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital Universitario Ramón y CajalMadrid, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07006727EU 2024-519111-34-00
- Record updated
- 22 September 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.Read full original descriptionShow less
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Inclusion: Age ≥ 18 years old; Patients with one of the following indications:; Dose Escalation Only:; Locally advanced, unresectable, or metastatic SCLC with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy (prior DLL3-targeted therapy allowed); LCNEC of the lung with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy; Metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC) confirmed by local histopathology, for whom no standard therapy is available, tolerated, or appropriate, in the investigator's judgment. Prior RLT is not allowed, though exceptions can be made following discussion with Novartis Medical Monitor; Locally advanced, unresectable, or metastatic GEP-NEC, cervical NEC, genitourinary NEC, thymic NEC, Merkel cell carcinoma, or unknown primary NEC with disease progression following, or intolerance to, at least one line of systemic therapy (including platinum-containing chemotherapy for non-MCC indications, or PD-1 or PD-L1 inhibition for MCC, unless patient was ineligible to receive such therapy), and for whom no standard therapy is available, tolerated, or appropriate, in the investigator's judgment; Locally advanced, unresectable, or metastatic medullary thyroid cancer with disease progression following, or intolerance to, at least 1 line of systemic therapy (unless patient was ineligible to receive such therapy), and for whom no standard therapy is available, tolerated, or appropriate, in the investigator's judgment; Dose expansion only:; Locally advanced, unresectable, or metastatic SCLC with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum-containing chemotherapy (prior DLL3-targeted therapy allowed). Patients should have received no more than 2 prior lines of systemic therapy; Locally advanced, unresectable, or metastatic GEP-NEC, with disease progression following, or intolerance to, at least 1 line of systemic therapy, including platinum containing chemotherapy. Patients must have at least one measurable lesion (per RECIST 1.1) that shows 111In-ETN029 uptake higher than surrounding tissues on SPECT/CT as assessed by the Investigator; Locally advanced, unresectable, or metastatic de novo or castration-resistant, treatment emergent NEPC with neuroendocrine differentiation confirmed by local histology and NEPC marker expression (e.g., chromogranin, synaptophysin) confirmed by local IHC. Prior PSMA-targeted, Lu-177-based RLT is allowed. Patients must have at least one measurable lesion (per RECIST 1.1) that shows 111In-ETN029 uptake higher than surrounding tissues on SPECT/CT as assessed by the Investigator.
Exclusion: Any prior DLL3-targeted therapy (except for SCLC); Any prior RLT (except for NEPC patients in expansion); Other protocol-defined inclusion/exclusion criteria may apply; Presence of leptomeningeal disease, of symptomatic CNS metastases or of CNS metastases that require local CNS-directed therapy; History of or current interstitial lung disease or pneumonitis ≥ Grade 2; Absolute neutrophil count (ANC) < 1.0 x 10\^9/L, hemoglobin < 9 g/dL, or platelet count < 75 x 10\^9/L; QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec; eGFR < 60 mL/min/1.73m2 calculated using the CKD-EPI 2021 formula or measured; Unmanageable urinary tract obstruction or urinary incontinence.